COVID-19 vaccination and breakthrough infections in patients with cancer
Schmidt A, Labaki C, Hsu C, Bakouny Z, Balanchivadze N, Berg S, Blau S, Daher A, Zarif T, Friese C, Griffiths E, Hawley J, Hayes-Lattin B, Karivedu V, Latif T, Mavromatis B, McKay R, Nagaraj G, Nguyen R, Panagiotou O, Portuguese A, Puc M, Dutra M, Schroeder B, Thakkar A, Wulff-Burchfield E, Mishra S, Farmakiotis D, Shyr Y, Warner J, Choueiri T, Consortium C, Choueiri T, Duma N, Farmakiotis D, Grivas P, de Lima Lopes G, Painter C, Peters S, Rini B, Shah D, Thompson M, Warner J. COVID-19 vaccination and breakthrough infections in patients with cancer. Annals Of Oncology 2021, 33: 340-346. PMID: 34958894, PMCID: PMC8704021, DOI: 10.1016/j.annonc.2021.12.006.Peer-Reviewed Original ResearchConceptsSymptomatic COVID-19COVID-19 vaccineClinical features of patientsRisk of breakthrough infectionClinical efficacy of COVID-19 vaccinesFeatures of patientsSpectrum of patientsHistory of cancerRisk of severe outcomesEfficacy of COVID-19 vaccinesSevere COVID-19Robust antibody titersSystemic therapyActive immunosuppressionHematologic malignanciesBreakthrough infectionClinical efficacyClinical featuresImpaired immunityVaccinated patientsUnvaccinated patientsClinical trialsLethal infectionPatientsAntibody titers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply